{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:38:04Z","timestamp":1790188684456,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T00:00:00Z","timestamp":1479254400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1245\/s10434-016-5682-5","type":"journal-article","created":{"date-parts":[[2016,11,17]],"date-time":"2016-11-17T06:06:37Z","timestamp":1479362797000},"page":"1289-1294","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX)"],"prefix":"10.1245","volume":"24","author":[{"given":"Jeong Eun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sang","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Byung","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Ja","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Sik","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Sik","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Cheon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Won","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"5682_CR1","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.8484121","volume":"260","author":"LA Aaltonen","year":"1993","unstructured":"Aaltonen LA, Peltomaki P, Leach FS, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812\u20136.","journal-title":"Science."},{"key":"5682_CR2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1097\/PAS.0b013e31816401bb","volume":"32","author":"LIH Overbeek","year":"2008","unstructured":"Overbeek LIH, Ligtenberg MJL, Willems RW, et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol. 2008;32:1246\u201351.","journal-title":"Am J Surg Pathol."},{"key":"5682_CR3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.2005.01.086","volume":"23","author":"S Popat","year":"2005","unstructured":"Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609\u201318.","journal-title":"J Clin Oncol."},{"key":"5682_CR4","first-page":"917","volume":"10","author":"WS Samowitz","year":"2001","unstructured":"Samowitz WS, Curtin K, Ma KN, et al. Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomark Prev. 2001;10:917\u201323.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"5682_CR5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1056\/NEJMoa022289","volume":"349","author":"CM Ribic","year":"2003","unstructured":"Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247\u201357.","journal-title":"N Engl J Med."},{"key":"5682_CR6","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1200\/jco.2009.27.15_suppl.4001","volume":"27","author":"S Tejpar","year":"2009","unstructured":"Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60\/00 trial). J Clin Oncol. 2009;27:4001.","journal-title":"J Clin Oncol."},{"key":"5682_CR7","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1158\/1078-0432.CCR-07-0366","volume":"13","author":"A Malesci","year":"2007","unstructured":"Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13:3831\u20139.","journal-title":"Clin Cancer Res."},{"key":"5682_CR8","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2009.27.1825","volume":"28","author":"DJ Sargent","year":"2010","unstructured":"Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219\u201326.","journal-title":"J Clin Oncol."},{"key":"5682_CR9","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0140-6736(02)11402-4","volume":"360","author":"PL Barratt","year":"2002","unstructured":"Barratt PL, Seymour MT, Stenning SP, et al. DNA markers predicting benefit from adjuvant fluorouracil in patients with colon cancer: a molecular study. Lancet. 2002;360:1381\u201391.","journal-title":"Lancet."},{"key":"5682_CR10","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/djr153","volume":"103","author":"FA Sinicrope","year":"2011","unstructured":"Sinicrope FA, Foster NR, Thibodeau SN, et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst. 2011;103:863\u201375.","journal-title":"J Natl Cancer Inst."},{"key":"5682_CR11","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.2008.18.2071","volume":"27","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009;27:1814\u201321.","journal-title":"J Clin Oncol."},{"issue":"Suppl 15","key":"5682_CR12","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/jco.2008.26.15_suppl.4008","volume":"26","author":"DJ Sargent","year":"2008","unstructured":"Sargent DJ, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials (abstract). J Clin Oncol. 2008;26(Suppl 15):4008.","journal-title":"J Clin Oncol."},{"key":"5682_CR13","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s00384-006-0228-0","volume":"22","author":"J Warusavitarne","year":"2007","unstructured":"Warusavitarne J, Schnitzler M. The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. Int J Colorectal Dis. 2007;22:739\u201348.","journal-title":"Int J Colorectal Dis."},{"key":"5682_CR14","unstructured":"National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon cancer, version 3, 2014. https:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp ."},{"issue":"Suppl 6","key":"5682_CR15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/annonc\/mdt354","volume":"24","author":"R Labianca","year":"2013","unstructured":"Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi64\u201372.","journal-title":"Ann Oncol."},{"key":"5682_CR16","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andre","year":"2009","unstructured":"Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109\u201316.","journal-title":"J Clin Oncol."},{"key":"5682_CR17","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768\u201374.","journal-title":"J Clin Oncol."},{"key":"5682_CR18","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465\u201371.","journal-title":"J Clin Oncol."},{"key":"5682_CR19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00384-008-0504-2","volume":"23","author":"CI Muller","year":"2008","unstructured":"Muller CI, Schulmann K, Reinacher-Schick A, et al. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008;23:1033\u20139.","journal-title":"Int J Colorectal Dis."},{"key":"5682_CR20","first-page":"4297","volume":"30","author":"G Des Guetz","year":"2010","unstructured":"Des Guetz G, Lecaille C, Mariani P, et al. Prognostic impact of microsatellite instability in colorectal cancer patients treated with adjuvant FOLFOX. Anticancer Res. 2010;30:4297\u2013301.","journal-title":"Anticancer Res."},{"key":"5682_CR21","first-page":"5248","volume":"58","author":"CR Boland","year":"1998","unstructured":"Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248\u201357.","journal-title":"Cancer Res."},{"key":"5682_CR22","first-page":"4545","volume":"61","author":"A Loukola","year":"2001","unstructured":"Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res. 2001;61:4545\u20139.","journal-title":"Cancer Res."},{"key":"5682_CR23","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/jnci\/91.15.1295","volume":"91","author":"KC Halling","year":"1999","unstructured":"Halling KC, French AJ, McDonnell SK, et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst. 1999;91:1295\u2013303.","journal-title":"J Natl Cancer Inst."},{"key":"5682_CR24","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1158\/1078-0432.CCR-12-0605","volume":"18","author":"PG Gavin","year":"2012","unstructured":"Gavin PG, Colangelo LH, Fumagalli D, et al. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res. 2012;18:6531\u201341.","journal-title":"Clin Cancer Res."},{"key":"5682_CR25","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.1158\/1078-0432.CCR-11-1048","volume":"17","author":"A Zaanan","year":"2011","unstructured":"Zaanan A, Flejou JF, Emile JF, et al. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. Clin Cancer Res. 2011;17:7470\u20138.","journal-title":"Clin Cancer Res."},{"key":"5682_CR26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s00268-013-2120-8","volume":"37","author":"SY Oh","year":"2013","unstructured":"Oh SY, Kim do Y, Kim YB, Suh KW. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer. World J Surg. 2013;37:2497\u2013503.","journal-title":"World J Surg."},{"key":"5682_CR27","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00280-009-1206-3","volume":"66","author":"ST Kim","year":"2010","unstructured":"Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 2010;66:659\u201367.","journal-title":"Cancer Chemother Pharmacol."},{"key":"5682_CR28","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/jnci\/djt173","volume":"105","author":"P Lochhead","year":"2013","unstructured":"Lochhead P, Kuchiba A, Imamura Y, et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst. 2013;105:1151\u20136.","journal-title":"J Natl Cancer Inst."},{"key":"5682_CR29","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-05-0404","volume":"65","author":"WS Samowitz","year":"2005","unstructured":"Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65:6063\u20139.","journal-title":"Cancer Res."},{"key":"5682_CR30","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466\u201374.","journal-title":"J Clin Oncol."},{"key":"5682_CR31","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-11-2246","volume":"18","author":"S Ogino","year":"2012","unstructured":"Ogino S, Shima K, Meyerhardt JA, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res. 2012;18:890\u2013900.","journal-title":"Clin Cancer Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-016-5682-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-016-5682-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T10:15:36Z","timestamp":1601201736000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-016-5682-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["5682"],"URL":"https:\/\/doi.org\/10.1245\/s10434-016-5682-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}